论文部分内容阅读
临床上,约5～10%左右的消化性溃疡患者经H_2-受体拮抗剂治疗2～3个月,而溃疡仍未愈合者称为难治性溃疡。为估价对难治性溃疡者应用奥美拉唑每日40mg是否比继续应用H_2受体拮抗剂更为有效,作者等对107例经内镜证实的难治性消化性溃疡患者,采用随机双盲法进行临床对比研究。上述病人随机分为二组,一组为53例继续服用以前的H_2受体拮抗剂(西眯替丁或雷尼替丁)加用类似奥美拉唑的安慰剂;另一组54例患者每天早晨口服40mg奥美拉唑加用类似西咪替丁或雷尼替丁的安慰剂。治疗共持续8周,结果如下。奥美拉唑组54例中治疗4周时有46例(85%)溃疡
Clinically, about 5 to 10% of patients with peptic ulcer by H 2 -receptor antagonists for 2 to 3 months, while the ulcer is still not healed as refractory ulcer. To assess the use of omeprazole 40mg daily for refractory ulcer patients than the continued use of H_2 receptor antagonist is more effective, the author of 107 cases of endoscopically proven refractory peptic ulcer patients with random double Blind clinical comparative study. The above patients were randomized into two groups, one in 53 subjects who continued with their previous H 2 receptor antagonist (cimetidine or ranitidine) plus a placebo similar to omeprazole; the other 54 patients Omeprazole 40 mg orally every morning plus placebo similar to cimetidine or ranitidine. Treatment for a total of 8 weeks, the results are as follows. Of the 54 patients in the omeprazole group, 46 (85%) had ulcers at 4 weeks of treatment